Synucleinopathies encompass a group of neurodegenerative disorders characterized by abnormal accumulation of alpha-synuclein protein aggregates in the brain. While commonly associated with Parkinson’s disease, recent research has implicated synucleinopathies in Alzheimer’s disease and other dementias. In Alzheimer’s, alpha-synuclein aggregates have been found to co-exist with tau and beta-amyloid plaques, hallmark proteins of Alzheimer's pathology. This co-occurrence suggests a potential overlap in disease mechanisms or synergistic pathological effects. The presence of alpha-synuclein pathology in Alzheimer’s patients often correlates with more severe cognitive impairment and faster disease progression. Understanding the role of synucleinopathies in Alzheimer’s and dementia could lead to novel diagnostic markers and therapeutic strategies targeting multiple pathological pathways, offering hope for more effective treatments in the future.
Title : Make a difference
Jacqueline Tuppen, Dementia UK, United Kingdom
Title : Imaging brain clearance in Alzheimer’s disease
Jun Hua, Johns Hopkins University , United States
Title : Neuromodulation of scalp electroacupuncture in the treatment of autism spectrum disorder
Zhenhuan Liu, Nanhai Maternity and Children Hospital Affiliated to Guangzhou University of Chinese Medicine, China
Title : Neuroimaging-based evaluation of scalp acupuncture for neural repair and reorganization in children with cerebral palsy
Zhenhuan Liu, Nanhai Maternity and Children Hospital Affiliated to Guangzhou University of Chinese Medicine, China
Title : Neurophysiological change and cognitive response to levetiracetam in Alzheimer disease: Testing the missing mechanistic link
Christopher Hubler, Emergent Neural Systems Institute for Research, United States
Title : Healthcare professionals in Somaliland had low levels of knowledge and attitudes towards dementia care: A pilot survey
Mohamed Abdilahi Duale, Frantz Fanon University, Somalia